Silver Spring, Maryland — The U.S. Food and Drug Administration has issued an Early Alert concerning specific glucose monitoring systems manufactured by Abbott Diabetes Care, following the company’s recommendation to withdraw certain devices from the market. This alert arises from concerns that specific models of the FreeStyle Libre 3 Sensor and FreeStyle Libre 3 Plus Sensor could present inaccurate glucose readings, which may endanger individuals managing diabetes.
The FDA noted that the devices might incorrectly report low-glucose levels, potentially resulting in inappropriate treatment responses. Although no recall has been initiated, the FDA is taking precautionary measures due to the serious nature of these inaccuracies. Reports indicate that Abbott has logged seven fatalities and approximately 736 serious injuries associated with these particular devices, underscoring the urgency of the situation.
Importantly, the alert does not extend to other products in the FreeStyle Libre line, such as readers and mobile applications, which remain unaffected. Individuals using these glucose monitoring systems are encouraged to check whether their sensors are among those implicated in the alert. If so, Abbott has committed to providing a complimentary replacement for the faulty devices.
The FreeStyle Libre systems are widely available, sold through various platforms, including the company’s website, Amazon Pharmacy, Walgreens outlets, and medical supply stores. As such, users are advised to be vigilant as inaccurate readings sustained over time can lead to severely misguided treatment decisions.
The FDA issues Early Alerts as a method of informing the public and healthcare professionals regarding medical devices that could pose significant health risks, even when they do not yet meet the criteria for an official recall. This proactive communication is intended to help patients and providers make informed choices and safeguard health.
Patients and caregivers relying on these glucose monitoring systems are encouraged to stay informed about potential risks associated with their devices. The FDA has emphasized the importance of verifying the accuracy of glucose readings, especially during critical management periods for those living with diabetes.